| Biological Sciences | Lifetime | 49 | GB 7 | 99.99 |
| Cancer Research | Lifetime | 4 | GB 1 | 99.99 |
| Molecular Biology | Lifetime | 55 | GB 3 | 99.98 |
| Oncology | Lifetime | 53 | GB 2 | 99.91 |
| Genetics | Lifetime | 409 | GB 45 | 99.05 |
| Medical Genetics | Lifetime | 800 | GB 55 | 90.19 |
| Immunology and Allergy | Lifetime | 711 | GB 74 | 84.98 |
| Cancer Research | 2021-2025 | 161 | GB 10 | 91.52 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 3 | GB 1 | 99.99 |
| Angiogenesis and VEGF in Cancer | Lifetime | 5 | GB 1 | 99.97 |
| RNA modifications and cancer | Lifetime | 62 | GB 5 | 99.78 |
| Cancer therapeutics and mechanisms | Lifetime | 27 | GB 2 | 99.72 |
| Cancer, Lipids, and Metabolism | Lifetime | 36 | GB 5 | 99.78 |
| Cancer-related molecular mechanisms research | Lifetime | 80 | GB 2 | 99.55 |
| HER2/EGFR in Cancer Research | Lifetime | 30 | GB 3 | 99.80 |
| Estrogen and related hormone effects | Lifetime | 48 | GB 6 | 99.66 |
| Enzyme function and inhibition | Lifetime | 11 | GB 1 | 99.38 |
| Epigenetics and DNA Methylation | Lifetime | 118 | GB 14 | 99.59 |
| Cancer Cells and Metastasis | Lifetime | 72 | GB 7 | 99.54 |
| Cancer-related Molecular Pathways | Lifetime | 73 | GB 8 | 99.62 |
| Cancer Treatment and Pharmacology | Lifetime | 83 | GB 3 | 99.70 |
| Cancer Research and Treatments | Lifetime | 93 | GB 5 | 99.27 |
| Cell Adhesion Molecules Research | Lifetime | 141 | GB 13 | 99.42 |
| Ubiquitin and proteasome pathways | Lifetime | 135 | GB 15 | 99.24 |
| Breast Cancer Treatment Studies | Lifetime | 170 | GB 13 | 99.42 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 435 | GB 39 | 99.20 |
| Neuroblastoma Research and Treatments | Lifetime | 134 | GB 4 | 99.01 |
| Autophagy in Disease and Therapy | Lifetime | 138 | GB 6 | 99.02 |
| MicroRNA in disease regulation | Lifetime | 436 | GB 9 | 98.51 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 295 | GB 7 | 98.94 |
| ATP Synthase and ATPases Research | Lifetime | 102 | GB 11 | 98.44 |
| Immune cells in cancer | Lifetime | 268 | GB 16 | 98.46 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 168 | GB 16 | 98.48 |
| Metabolism, Diabetes, and Cancer | Lifetime | 354 | GB 29 | 98.61 |
| Fibroblast Growth Factor Research | Lifetime | 123 | GB 7 | 97.63 |
| Endoplasmic Reticulum Stress and Disease | Lifetime | 282 | GB 17 | 97.95 |
| Mitochondrial Function and Pathology | Lifetime | 724 | GB 66 | 97.96 |
| Neuroendocrine Tumor Research Advances | Lifetime | 497 | GB 31 | 98.28 |
| DNA Repair Mechanisms | Lifetime | 492 | GB 48 | 97.85 |
| Renal cell carcinoma treatment | Lifetime | 451 | GB 21 | 98.02 |
| Drug Transport and Resistance Mechanisms | Lifetime | 676 | GB 46 | 97.36 |
| Peptidase Inhibition and Analysis | Lifetime | 909 | GB 56 | 97.22 |
| Biochemical and Molecular Research | Lifetime | 480 | GB 43 | 97.02 |
| Lung Cancer Research Studies | Lifetime | 762 | GB 31 | 97.51 |
| Protease and Inhibitor Mechanisms | Lifetime | 570 | GB 44 | 96.64 |
| Colorectal Cancer Treatments and Studies | Lifetime | 990 | GB 50 | 97.28 |
| Histone Deacetylase Inhibitors Research | Lifetime | 462 | GB 19 | 95.89 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 832 | GB 55 | 96.40 |
| TGF-β signaling in diseases | Lifetime | 288 | GB 11 | 95.76 |
| High Altitude and Hypoxia | Lifetime | 383 | GB 37 | 95.44 |
| Nausea and vomiting management | Lifetime | 356 | GB 27 | 95.53 |
| Adrenal and Paraganglionic Tumors | Lifetime | 544 | GB 27 | 95.50 |
| Wnt/β-catenin signaling in development and cancer | Lifetime | 556 | GB 46 | 94.52 |
| Lymphatic System and Diseases | Lifetime | 394 | GB 35 | 92.67 |
| Kruppel-like factors research | Lifetime | 498 | GB 27 | 91.66 |
| Vascular Tumors and Angiosarcomas | Lifetime | 668 | GB 38 | 92.61 |
| Developmental Biology and Gene Regulation | Lifetime | 717 | GB 82 | 93.37 |
| Chemotherapy-induced organ toxicity mitigation | Lifetime | 297 | GB 15 | 90.38 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 775 | GB 31 | 89.12 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 861 | GB 33 | 88.06 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 51 | GB 2 | 97.85 |
| Cell Adhesion Molecules Research | 2021-2025 | 390 | GB 28 | 79.96 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 491 | GB 25 | 67.90 |
